FIG 5.
Competitive neutralization (FRA) assay using H1N1-specific antisera and mouse and human MAbs against the H1N1 CA/09 pandemic virus strains. (A to C) The extent of HAI titer reduction through competitive HAI using antisera from H1N1 CA/09 HA vaccinated mice. (D and E) IC50 value of MAb 1F8 (D) and MAb IC5-4F8 (E) against H1N1 pandemic (CA/09) influenza virus strains following preabsorption with rHAΔSA protein representing seasonal (NC/99) and pandemic (CA/09) virus strains. Differences in the neutralizing activity at different dilutions (sera) or concentrations (MAbs) were analyzed using a one-way ANOVA (*, P < 0.05; **, P < 0.01).